H. Hernan

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

J. Kolesar, KyungMann Kim, T. Campbell, 2014, Investigational New Drugs.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.

Herb Chen, K. Wisinski, G. Leverson, 2013 .

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

D. Deming, T. Goggins, S. Lubner, 2013, Investigational New Drugs.

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

J. Kolesar, M. Jones, T. Campbell, 2011, Journal of Clinical Oncology.